<DOC>
	<DOCNO>NCT00255983</DOCNO>
	<brief_summary>Identifying role antibiotic treatment subject microbiologically document acute exacerbation chronic bronchitis ( AECB ) purpose clinical trial . The trial design evaluate efficacy safety faropenem medoxomil versus placebo treatment subject microbiologically document AECB .</brief_summary>
	<brief_title>A Trial Evaluate Efficacy Safety Faropenem Medoxomil In Treatment Chronic Bronchitis</brief_title>
	<detailed_description>This multi-center , multi-national , prospective , randomize , double-blind , placebo-controlled study evaluate efficacy safety/tolerability faropenem medoxomil versus placebo treatment subject primary diagnosis AECB . All subject pre-therapy sputum specimen obtain culture susceptibility testing .</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<criteria>Male nonpregnant female outpatient age great equal 35 year significant COPD ( GOLD criterion I , IIA IIB ) , chronic cough sputum production acute exacerbation Gold criterion III</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>bronchitis</keyword>
	<keyword>AECB</keyword>
</DOC>